The Tirzepatide 5 mg Sweet Spot: What the Data Shows
SURMOUNT-1 subgroup data shows some patients hit their goals at 5 mg tirzepatide and gain little from stepping up. Here's how to read the cost/side-effect curve.
May 28, 2026 · 7 min read · By GLP-FAQ Editors
Standard titration advice for tirzepatide points toward the highest dose you can tolerate. The prescribing information for Zepbound starts at 2.5 mg, steps to 5 mg after four weeks, then continues stepping up every four weeks to the eventual maintenance dose — typically 10 mg or 15 mg. The implication is that higher is better, and 5 mg is just a stepping stone.
The SURMOUNT-1 trial data tells a more interesting story. Tirzepatide 5 mg produced substantial, clinically meaningful weight loss in a significant portion of participants — and the marginal benefit of stepping up is not uniformly distributed. For some patients, 5 mg represents a genuine maintenance option rather than an intermediate stop.
This is the data you need to have an informed conversation with your prescriber about dose.
What SURMOUNT-1 Showed at Each Dose
SURMOUNT-1 was a 72-week Phase 3 trial comparing tirzepatide at 5 mg, 10 mg, and 15 mg to placebo in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The primary endpoint was percentage change in body weight from baseline.
Results at 72 weeks:
| Dose | Mean weight loss | ≥5% responders | ≥15% responders | ≥20% responders |
|---|---|---|---|---|
| Placebo | −3.1% | 31% | 5% | 1% |
| 5 mg | −15.0% | 89% | 55% | 30% |
| 10 mg | −19.5% | 96% | 69% | 46% |
| 15 mg | −20.9% | 96% | 73% | 52% |
Three things stand out. First, even the 5 mg dose produces meaningful results that far exceed placebo. Second, moving from 5 mg to 10 mg added approximately 4.5 percentage points of mean weight loss. Third, moving from 10 mg to 15 mg added only about 1.4 percentage points of mean weight loss — a much smaller marginal gain.
The ≥15% responder column matters for goal-setting. At 5 mg, 55% of participants lost at least 15% of body weight. That's a threshold often cited as the level at which cardiovascular and metabolic benefits become clinically significant. More than half of 5 mg users crossed it.
The Subgroup Picture: Who Does Well at 5 mg
The aggregate mean conceals meaningful heterogeneity. Some patients on 5 mg lose 25%; others lose 8%. Subgroup analyses from SURMOUNT-1 and related SURMOUNT studies identified characteristics associated with stronger response at lower doses:
Higher baseline weight loss per unit of drug. People who showed rapid and substantial weight loss in the first 12–16 weeks of 5 mg treatment tended to continue responding well without stepping up. Early responders — roughly defined as ≥8–10% weight loss in the first 16 weeks — had less incremental benefit from dose escalation than slower initial responders.
Lower body weight at baseline. People with lower starting BMIs (in the 27–33 range) often achieved their weight loss goals at 5 mg without needing higher doses. The ceiling effect of the drug's appetite suppression is more likely to produce the desired outcome at a lower BMI than at a higher one.
Better GI tolerability at 5 mg. Side effects — particularly nausea, diarrhea, and constipation — are dose-dependent in tirzepatide. Patients who experience significant GI symptoms at 5 mg are less likely to tolerate higher doses; patients who tolerate 5 mg well and who are losing weight at a satisfying rate may have little reason to step up and accept additional side-effect burden.
This doesn't mean stepping up is wrong for these patients. It means stepping up is a decision, not a mandatory next step.
The Cost/Side-Effect Curve
Tirzepatide's cost (for patients without insurance coverage or with high out-of-pocket exposure) is meaningfully dose-dependent. List prices as of early 2026:
| Dose | Approximate monthly list price |
|---|---|
| 2.5 mg (titration) | ~$1,060 |
| 5 mg | ~$1,060 |
| 7.5 mg | ~$1,060 |
| 10 mg | ~$1,060 |
| 12.5 mg | ~$1,060 |
| 15 mg | ~$1,060 |
Eli Lilly prices Zepbound at a flat rate per pen regardless of dose, which changes the pure cost calculation. However, for patients using compounded tirzepatide — which is priced per milligram — the cost difference between 5 mg/week and 15 mg/week is substantial.
For compounded tirzepatide users, the cost difference between doses is real and compounds monthly. If 5 mg is producing satisfactory weight loss, staying at 5 mg represents a meaningful cost advantage that also comes with reduced side-effect burden.
Even for brand Zepbound users, the side-effect curve alone may justify a 5 mg maintenance dose. GI side effects from tirzepatide are clearly dose-dependent. Nausea, diarrhea, and constipation at 10–15 mg were roughly 10–15 percentage points more prevalent than at 5 mg in SURMOUNT-1. For someone who loses 14% of body weight at 5 mg and is satisfied with that outcome, accepting higher GI burden for an additional 5–6% weight loss is a value judgment worth making deliberately.
The "Stepping Down" Question
A related concept — covered more thoroughly in the stepping-down tirzepatide dose post — is stepping down to 5 mg after reaching a higher maintenance dose. Some patients overshoot their weight loss goals at 10 mg or 15 mg (losing more weight than they intended), and stepping down to 5 mg allows them to maintain current weight rather than continuing to lose.
The SURMOUNT-5 data on maintenance dosing is relevant here: patients who continued on tirzepatide maintained most of their weight loss, while those who switched to placebo regained significantly. The maintenance dose doesn't need to be the dose that produced weight loss — it needs to be the dose that prevents regain, which for some patients is lower.
When 5 mg Probably Isn't Enough
There are clear cases where staying at 5 mg is likely to underserve the patient:
- High BMI with significant metabolic disease. Someone with BMI ≥40 and type 2 diabetes, hypertension, and sleep apnea probably needs more than 15% weight loss to see substantial disease improvement. The higher doses that produce 20%+ weight loss are more likely to be clinically meaningful.
- Slow or no response in the first 12–16 weeks. If you've been on 5 mg for 16 weeks and lost less than 5% of body weight, the drug is likely not achieving adequate suppression at this dose for your physiology. Stepping up is appropriate.
- Weight loss plateau before goal. If you've lost weight but stopped well short of your clinical target, stepping up is the most straightforward intervention before adding other approaches.
Prescribers generally recommend stepping up by default because most patients benefit from higher doses. The point here isn't that 5 mg is the right answer for everyone — it's that it's the right answer for a meaningful subset, and that conversation is worth having.
How to Talk to Your Prescriber About Staying at 5 mg
The most productive conversation starts with outcomes:
- "I've been on 5 mg for 20 weeks and I've lost X% of body weight."
- "I've hit [specific goal — e.g., BMI under 30, resolution of prediabetes, target weight]."
- "My main side effects at 5 mg are [minimal/manageable]."
- "I'd like to discuss whether stepping up is likely to add meaningfully for me, given where I am."
Your prescriber can pull your 12- and 16-week weight data to assess your response trajectory and make a more individualized recommendation. The SURMOUNT-1 subgroup data gives them clinical cover to consider 5 mg as a maintenance dose — this is not a fringe position.
See the tirzepatide dosing schedule page for the full standard titration protocol, and when to step up tirzepatide for the clinical criteria typically used to guide dose escalation decisions.
Related reading
Free weekly newsletter
Get the GLP-1 highlights, weekly.
One short email a week — new FAQs, trial readouts, supply updates, and dosing tips. Plain-English, no spam.
Unsubscribe anytime. We never share your email.